LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Immatics US, Inc.
Acepodia Biotech, Inc.
Fate Therapeutics
Mie University
Mie University